Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
نویسندگان
چکیده
منابع مشابه
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
PURPOSE PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated liposomal drugs in a C26/tk-luc colon carcinoma-bearing mouse model. METHODS Empty PEGylated liposo...
متن کاملPegylated liposomal doxorubicin in ovarian cancer
The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enha...
متن کاملPegylated liposomal doxorubicin in ovarian cancer
Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Ph...
متن کاملClinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation. Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelia...
متن کاملPegylated liposomal doxorubicin in the treatment of mycosis fungoides.
Sir, Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. It typically evolves from the early patch and plaque stage to the cutaneous nodular or tumour stage and sometimes visceral involvement is seen in the later stage. MF is also present in an erythrodermic variant accompanied by lymphadenopathy and peripheral blood involvement, known as Sézary syndrome (1). A number of differ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2013
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0063078